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Background
The soluble guanylyl cyclase (sGC) is a key enzyme
involved in the production of the second messenger
cGMP. Due its cardiovascular relevance, sGC has been
the target of numerous drug discovery efforts leading to
the development of many different activators and stimu-
lators with pharmaceutical potential. One of such com-
pounds is the sGC activator Cinaciguat (BAY 58-2667)
which is in clinical trials for acute decompensated heart
failure.
Results
We present here our latest structure-function studies
related to sGC activation by different sGC activators.
The activator complex structures reveal an intriguing
mode of heme mimicry by these compounds. The
observed activation conformational changes center
around the aF helix that contains the H105 residue nor-
mally held in place by the heme moiety in the absence
of the activators.
Conclusion
The structural insights gained from the complex struc-
tures could be used for further optimization and devel-
opment of sGC activators.
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